StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Formulary Update a Net Positive for Gilead Sciences (GILD), Negative for Enanta (ENTA) - RBC
August 7, 2018 10:34 AM
RBC Capital analyst Brian Abrahams said the Express Scripts formulary update is a net positive for Gilead Sciences (NASDAQ: GILD) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Trader Talk
Next Articles
Enanta Pharmaceuticals (ENTA) PT Lowered to $90 at RBC Capital
August 8, 2018 8:33 AM
Formulary Update Positive for Mylan (MYL) - Evercore ISI
August 7, 2018 10:05 AM
Express Scripts (ESRX) Announces 2019 National Preferred Formulary Exclusion List Changes
August 7, 2018 8:10 AM
Express Scripts (ESRX) to Drop Big Sellers from AbbVie (ABBV), Gilead Sciences (GILD) in 2019 - Bloomberg
August 7, 2018 8:01 AM